KALA BIO Inc
KALA
NASDAQ
Biotechnology
$0.95
USD
+0.02 (+2.33%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $17.79M
Volume 30.5K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-19.65M
TTM
+44.9%
YoY
Operating Cash Flow
$-26.06M
TTM
+4.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 4.6 | 4.6 | 4.5 | 9.9 | 1.7 |
Other Operating Expenses | 0.0 | 0.2 | -3.4 | 0.0 | 0.0 |
Total Operating Expenses | 10.7 | 11.0 | 7.2 | 10.2 | 1.8 |
Operating Income | -10.7 | -11.0 | -7.2 | -10.2 | -1.8 |
EBITDA | -10.6 | -10.8 | -10.5 | -5.5 | -1.8 |
Other Income / Expense | 2.4 | 0.5 | 0.4 | 11.1 | 0.1 |
Total Other Income / Expense | 1.7 | -0.1 | -0.3 | 10.9 | 0.2 |
Income Before Income Taxes | -8.9 | -11.2 | -7.6 | 0.7 | -1.6 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -8.9 | -11.2 | -7.6 | 0.7 | -1.6 |
Consolidated Net Income / Loss | -8.9 | -11.2 | -7.6 | 0.7 | -1.6 |
Net Income Attributable to Common Shareholders | -8.9 | -11.2 | -7.6 | 0.7 | -1.6 |
Basic EPS | -$70.49 | -$85.50 | -$53.50 | $2.70 | -$0.14 |
Diluted EPS | -$70.49 | -$85.50 | -$53.50 | $2.70 | -$0.14 |
Basic Shares Outstanding | 0.1M | 0.1M | 0.1M | 0.3M | 11.9M |
Diluted Shares Outstanding | 0.1M | 0.1M | 0.1M | 0.3M | 11.9M |